In a confidence survey from Deloitte and the National Venture Capital Association, respondents lacked faith in the future of the biopharma industry, and the low confidence bodes poorly for an industry already suffering from dwindling VC dollars.
Fresh doubts have cropped up for raising "good cholesterol" to combat heart attack risk, after a new study showed that patients genetically programmed to have higher levels of HDL cholesterol didn't appear to be more protected from heart disease than those with low levels.
Big Pharma companies have been farming out more of their R&D in recent years to keep spending in check, yet the experts have clashed over how much outsourcing can be done without threatening the
John LaMattina has provided some new insights from his past days inside the belly of the Pfizer beast, this time in a candid interview with Pharmalot's Ed Silverman. And the drug giant's former
John LaMattina doesn't have much to say in favor of Pfizer's business strategy over recent years. In a piece for Nature, the former Pfizer ( $PFE ) R&D chief marshals his arguments against the Big
John LaMattina has some advice for Pfizer ( $PFE ), where he worked for 30 years before retiring as the head of research. Once the pharma giant finishes chopping the R&D budget to around $6.5
There's nothing new about partnering in drug development. It's been going on for years. But the mantra on collaboration is becoming an article of faith these days, as a new analysis piece from
John LaMattina, Pfizer's former R&D chief, has made the leap into the venture field, joining PureTech Ventures as a senior partner. After putting in 30 years at the drug giant, LaMattina retired
Avant Immunotherapeutics today announced the departure of Una Ryan, Ph.D, President and CEO, effective immediately. Watson Pharmaceuticals announced that co-founder and Chairman Allen Chao has
Jeffrey Kindler's plans to shake up Pfizer have led to the departure of two top executives. John LaMattina, global head of research, will retire and Alan Levin resigned as chief financial officer,